MIRA Pharmaceuticals: A New Hope for Neuropathic Pain Sufferers

MIRA Pharmaceuticals, a preclinical-stage biopharmaceutical company, has initiated human trials for its novel oral ketamine analog, Ketamir-2, in Israel. This drug candidate has shown promising preclinical results, demonstrating 60% greater efficacy than the FDA-approved neuropathic pain treatment gabapentin in reducing chemotherapy-induced pain. The successful completion of these trials could have significant implications for MIRA Pharmaceuticals' market valuation and investor confidence, as well as the competitive landscape of the global neuropathic pain market.